



### TABLE OF CONTENTS

---

|   |                                 |            |
|---|---------------------------------|------------|
| ● | <b>Description</b>              | <b>p.1</b> |
| ● | <b>Impact Factor</b>            | <b>p.1</b> |
| ● | <b>Abstracting and Indexing</b> | <b>p.1</b> |
| ● | <b>Editorial Board</b>          | <b>p.2</b> |
| ● | <b>Guide for Authors</b>        | <b>p.4</b> |



ISSN: 1879-4068

### DESCRIPTION

---

The *Journal of Geriatric Oncology* is an international, multidisciplinary journal which is focused on advancing research in the **treatment** and survivorship issues of older adults with **cancer**, as well as literature relevant to education and policy development in **geriatric oncology**.

Editor-in-Chief, Supriya Mohile, University of Rochester, USA and the [Editorial Board](#) invite you to [submit](#) a manuscript to the *Journal of Geriatric Oncology*. The journal welcomes the submission of manuscripts in the following categories:

- Original research articles
- Review articles
- Clinical trials
- Education and training articles
- Short communications
- Perspectives
- Meeting reports
- Letters to the Editor

The *Journal of Geriatric Oncology* is the official journal of the [International Society of Geriatric Oncology \(SIOG\)](#).

### IMPACT FACTOR

---

2019: 2.761 © Clarivate Analytics Journal Citation Reports 2020

### ABSTRACTING AND INDEXING

---

Science Citation Index Expanded  
Journal Citation Reports - Science Edition  
Current Contents - Clinical Medicine  
Scopus

## EDITORIAL BOARD

---

### *Editor-in-Chief*

**Supriya Mohile**, University of Rochester Medical Center, Rochester, New York, United States

### *Deputy Editor*

**Shabbir Alibhai**, University Health Network, Toronto, Ontario, Canada

**Siri Rostoft**, University of Oslo, Oslo, Norway

### *Social Media Editor*

**William Dale**, City of Hope National Medical Center, Duarte, California, United States

### *Associate Editors*

**M E Hamaker**, Diakones Hospital Utrecht Zeist Doorn Location Zeist, Zeist, Netherlands

**H. Klepin**, Wake Forest University School of Medicine, Winston-Salem, North Carolina, United States

**K. P. Loh**, University of Rochester Medical Center, Rochester, New York, United States

**M. Puts**, University of Toronto, Toronto, Ontario, Canada

**E. Soto-Perez-de-Celis**, Mexico National Cancer Institute, Mexico City, Mexico

**W. Tew**, Memorial Sloan Kettering Cancer Center, New York, United States

**N. VanderWalde**, The University of Tennessee Health Science Center, Memphis, Tennessee, United States

**T. Wildes**, Washington University in St Louis School of Medicine, Saint Louis, Missouri, United States

**G. R. Williams**, The University of Alabama at Birmingham, Birmingham, Alabama, United States

### *Founding Editor*

**Matti S. Apro**, Genolier, Switzerland

**Arti Hurria**, Duarte, California, United States

### *Advisory Board*

**Lodovico Balducci**, H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, Tampa, Florida, United States

**Harvey Cohen**, Duke University Medical Center, Durham, North Carolina, United States

**Jean-Pierre Droz**, Centre Leon Berard, Lyon, France

**Margaret Kemeny**, Icahn School of Medicine at Mount Sinai, New York, New York, United States

**Silvio Monfardini**, Don Gnocchi Foundation, Milano, Italy

**Hyman Muss**, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina, United States

**Louise Walter**, University of California San Francisco, San Francisco, California, United States

### *Editorial Board Members*

**Amina Ahmed**, Rush University Medical Center, Chicago, Illinois, United States

**Thomas Aparicio**, Saint Louis Hepato-Gastroenterology Hospital, Paris, France

**Kimlin Tam Ashing-Giwa**, City of Hope National Medical Center, Duarte, California, United States

**Riccardo A. Audisio**, University of Gothenburg, Gothenburg, Sweden

**Etienne Audureau**, University Paris-Est Créteil Val de Marne, Creteil, France

**Gouri Shankar Bhattacharyya**, Fortis Hospital Anandapur, Anandapur, India

**Laura Biganzoli**, Ospedale di Prato Santo Stefano, Prato, Italy

**Etienne Brain**, René Huguenin Hospital Saint-Cloud, Saint-Cloud, France

**Philippe Caillet**, Hospital Henri Mondor, Creteil, France

**Karis Kin Fong Cheng**, National University of Singapore, Singapore

**Kwok Leung Cheung**, University of Nottingham School of Medicine, Derby, United Kingdom

**Stephen Chun**, UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER, Houston, Texas, United States

**Raul Cordoba**, Hospital Universitario Fundacion Jimenez Diaz, Madrid, Spain

**Lore Decoster**, UZ Brussel, Brussel, Belgium

**Efrat Dotan**, Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

**Martine Extermann**, H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, Tampa, Florida, United States

**Fergal Fleming**, University of Rochester Medical Center, Rochester, New York, United States

**Holly Holmes**, UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER, Houston, Texas, United States

**Aminah Jatoi**, Mayo Clinic Rochester, Rochester, Minnesota, United States

**Ravindran Kaneshwaran**, National Cancer Centre Singapore, Singapore, Singapore

**Nancy Keating**, Harvard Medical School, Boston, Massachusetts, United States

**Cindy Kenis**, KU Leuven University Hospitals Leuven, Leuven, Belgium

**Gretchen Kimmick**, Duke University Medical Center, Durham, North Carolina, United States

**Beatriz Korc**, Memorial Sloan Kettering Cancer Center, New York, United States

**Stuart Lichtman**, Memorial Sloan Kettering Cancer Center, New York, United States

**Lisa M. Lowenstein**, UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER, Houston, Texas, United States

**Andrea Luciani**, Ospedale S. Chiara, Pisa, Italy

**Jennifer L. Lund**, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States  
**Ronald Maggiore**, University of Rochester Medical Center, Rochester, New York, United States  
**Allison Magnuson**, University of Rochester, Rochester, New York, United States  
**June M. McKoy**, Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States  
**Vicki Morrison**, University of Minnesota, Minneapolis, Minnesota, United States  
**Arash Naeim**, University of California Los Angeles David Geffen School of Medicine, Los Angeles, California, United States  
**Christian Nelson**, Memorial Sloan Kettering Cancer Center, New York, United States  
**Gina Nightingale**, Thomas Jefferson University, Philadelphia, Pennsylvania, United States  
**Tracey O'Connor**, ROSWELL PARK CANCER INSTITUTE, Buffalo, New York, United States  
**Anita O'Donovan**, The University of Dublin Trinity College, Dublin, Ireland  
**Rebecca Olin**, University of California San Francisco, San Francisco, California, United States  
**Cynthia Owusu**, Case Western Reserve University School of Medicine, Cleveland, Ohio, United States  
**Athanasios G. Pallis**, Institut Servier SAS, Suresnes, France  
**Johanneke Portielje**, Leiden University Medical Center, Leiden, Netherlands  
**Erika Ramsdale**, University of Rochester, Rochester, New York, United States  
**Miriam B. Rodin**, Saint Louis University School of Medicine, Saint Louis, Missouri, United States  
**Ashley Rosko**, OHIO STATE UNIVERSITY, Columbus, Ohio, United States  
**Armin Shahrokni**, Memorial Sloan Kettering Cancer Center, New York, United States  
**Ponnandai S. Somasundar**, Roger Williams Medical Center, Providence, Rhode Island, United States  
**Reinhard Stauder**, Medical University of Innsbruck, Innsbruck, Austria  
**Christopher Steer**, Albury Wodonga Regional Cancer Centre Trust Fund Inc, Albury, New South Wales, Australia  
**Catherine Terret**, Centre Leon Berard, Lyon, France  
**Kelly M. Trevino**, NewYork-Presbyterian Hospital/Weill Cornell Medical Center, New York, New York, United States  
**Barbara L. Van Leeuwen**, University Medical Centre Groningen, Groningen, Netherlands  
**Ulrich Wedding**, Friedrich Schiller University Jena, Jena, Germany  
**Hans Wildiers**, KU Leuven, Leuven, Belgium

***Editorial Office***

**Lisa Lovheim**

## GUIDE FOR AUTHORS

---

### INTRODUCTION

The *Journal of Geriatric Oncology* is an international, multidisciplinary journal focused on advancing research in the pathogenesis, biology, treatment, and survivorship issues of older adults with cancer. The journal covers all aspects of geriatric oncology, from basic scientific research through to clinical research, as well as research that is relevant to education and policy development.

This journal operates a single blind review process. All contributions will be initially assessed by the editor for suitability for the journal. Papers deemed suitable are then sent to a minimum of two independent expert reviewers to assess the scientific quality of the paper. The Editor is responsible for the final decision regarding acceptance or rejection of articles. The Editor's decision is final. [More information](#) on types of peer review.

The *Journal of Geriatric Oncology* publishes original research articles, review articles, clinical trials, treatment guidelines, short communications, and letters to the editor which comment on previously published work.

The *Journal of Geriatric Oncology* is the official journal of the International Society of Geriatric Oncology (SIOG).

### **Manuscript categories and guidelines**

The *Journal of Geriatric Oncology* publishes articles in the following categories:

**Editorials:** Editorials are invited by the Editor-in-Chief. Editorials do not have an abstract or keywords and should be limited to 1,500 words in length.

**Original Research Articles:** Original, full-length research papers which have not been published previously, except in a preliminary form, may be submitted. Original research papers should include a structured abstract (250 words) and should be divided into sections (Introduction, Materials and Methods, Results and Discussion). They should not exceed 3,500 words in length.

Papers reporting the results of clinical trials may be submitted. Clinical trial papers should indicate a structured abstract (250 words) and should be divided into sections (Introduction, Materials and Methods, Results and Discussion). They should not exceed 3,500 words in length.

**Review Articles:** Review articles which are topical and which are a critical assessment of any aspect of geriatric oncology may be submitted. Review articles should include an unstructured abstract [250 words]. They should not exceed 5,000 words in length.

**Education and Training Articles:** Full-length papers which report on education and training initiatives in geriatric oncology may be submitted. Education and training articles should include a structured abstract (250 words) and should be divided into sections (Introduction, Materials and Methods, Results and Discussion). They should not exceed 3,500 words in length.

**Short Communications:** Short communications provide a brief but complete account of a piece of work. They should have a structured abstract (250 words) and should be divided into sections (Introduction, Materials and Methods, Results and Discussion). Short communications should have no more than ten references and should not exceed 2,000 words in length.

**Perspectives:** Perspectives papers are invited by the Editor-in-Chief. They are short communications in which individuals involved with the field of geriatric oncology comment on aspects of care or research which have shaped their thinking and their practice. Perspectives papers do not have an abstract and are limited to 1,500 words.

**Meeting Reports:** Reports on geriatric oncology conferences, meetings and workshops are welcomed, although authors are recommended to discuss their proposal first with the Editor-in-Chief. Meeting reports do have an abstract and keywords and should not exceed 3,000 words in length.

*Letters to the Editor:* Letters of 1,500 words or less which relate to previously published work from the *Journal of Geriatric Oncology* or original research matters of interest to researchers in our field may be submitted. If commenting on a previously published paper the Editor-in-Chief may choose to invite a reply from the authors of the paper on which the letter is commenting. Letters consist of 10 references, 1 figure, and 1 table, no abstract.

*Case Reports:* JGO does not publish Case Reports. You may consider submitting your case report to [Current Problems in Cancer: Case Reports](#), a Journal which aims to fortify the field of oncology by publishing original case reports featuring prevention, diagnosis and treatment of cancer, supportive care, quality of life and rehabilitation.

### **Submission checklist**

It is hoped that this list will be useful during the final checking of an article prior to sending it to the journal's Editor for review. Please consult this Guide for Authors for further details of any item.

#### **Ensure that the following items are present:**

- One author designated as corresponding author:  
E-mail address  
Full postal address
- [Authorship Contribution](#)
- [ICMJE Disclosure form](#)
- All necessary files have been uploaded
- Keywords
- All figure captions
- All tables (including title, description, footnotes)

All manuscripts reporting on original research require a statement that an IRB/ ethics committee has reviewed it and that the research meets requirements for protection of human subjects.

**IMPORTANT:** JGO requires that authors submit ICMJE form for **ALL** authors and an authorship contribution form.

#### *Further considerations*

- The Journal of Geriatric Oncology prefers authors to reference in their paper the following terms:

"patients with cancer" rather than "cancer patients" "older patient with cancer" instead of "older cancer patient" "older patient with cancer" instead of "elderly cancer patient" "older patients" instead of "elderly"

More details are provided in the editorial by Lundebjerg, et al, When It Comes to Older Adults, Language Matters: JAGS Adopts Modified American Medical Association Style. *J Am Geriatr Soc* 65:1132-1133.

- Manuscript has been "spell-checked" and "grammar-checked"
- Please include a comma for numbers 1,000 or 1,000,000
- Use the Oxford (Serial) comma when there is a list of three or more items (e.g., written as "dogs, cats, and pigs" as opposed to "dogs, cats and pigs")
- Numbers that are less than 20 should be written (does not apply to tables, figures).
- Use a maximum of 3 significant figures (i.e. p 0.001).
- Prior to submitting please check that data described in the manuscript matches data in the Tables and Figures and that data in Tables and Figures is accurate. If there is missing data or data that is overlapping (for data that should add up to 100%), please note these numbers in the legend.
- Please ensure that all Tables and Figures are referenced in the manuscript
- Please ensure that all abbreviations are spelled out at first use. All abbreviations in Tables and Figures should be spelled out in a legend.
- References are in the correct format for this journal
- Permission has been obtained for use of copyrighted material from other sources (including the Web)
- Colour figures are clearly marked as being intended for colour reproduction on the Web (free of charge) and in print or to be reproduced in colour on the Web (free of charge) and in black-and-white in print

- If only colour on the Web is required, black and white versions of the figures are also supplied for printing purposes
- Conflict of interest and disclosures as well as author contributions have been provided at the end of the manuscript before the reference section.
- For any further information please visit [www.elsevier.com/authors](http://www.elsevier.com/authors).

### **Data references**

This journal encourages you to cite underlying or relevant datasets in your manuscript by citing them in your text and including a data reference in your Reference List. Data references should include the following elements: author name(s), dataset title, data repository, version (where available), year, and global persistent identifier. Add [dataset] immediately before the reference so we can properly identify it as a data reference. This identifier will not appear in your published article.

Example:

For any further information please visit [www.elsevier.com/authors](http://www.elsevier.com/authors).

[dataset] [1] Oguro M, Imahiro S, Saito S, Nakashizuka T. Mortality data for Japanese oak wilt disease and surrounding forest compositions, Mendeley Data, v1; 2015. <http://dx.doi.org/10.17632/xwj98nb39r.1>.

### **General information**

The *Journal of Geriatric Oncology* will consider manuscripts prepared according to the guidelines adopted by the International Committee of Medical Journal Editors ("Uniform requirements for manuscripts submitted to biomedical journals", available as a PDF from <http://www.icmje.org>). Authors are advised to read these guidelines.

Submission of an article implies that the work described has not been published previously (except in the form of an abstract or as part of a published lecture or academic thesis), that it is not under consideration for publication elsewhere, that its publication is approved by all authors and tacitly or explicitly by the responsible authorities where the work was carried out, and that, if accepted, it will not be published elsewhere in the same form, in English or in any other language, without the written consent of the copyright holder. To verify originality, your article may be checked by the originality detection software iThenticate. See also: <https://www.elsevier.com/editors/plagdetect>

Upon acceptance of an article, authors will be asked to sign a 'Journal Publishing Agreement' (for more information on this and copyright see <https://www.elsevier.com/copyright>). Acceptance of the agreement will ensure the widest possible dissemination of information. An e-mail (or letter) will be sent to the corresponding author confirming receipt of the manuscript together with a 'Journal Publishing Agreement' form or a link to the online version of this agreement.

Subscribers may reproduce tables of contents or prepare lists of articles including abstracts for internal circulation within their institutions. Permission of the Publisher is required for resale or distribution outside the institution and for all other derivative works, including compilations and translations (please consult <https://www.elsevier.com/permissions>).

If excerpts from other copyrighted works are included, the author(s) must obtain written permission from the copyright owners and credit the source(s) in the article. Elsevier has preprinted forms for use by authors in these cases: please consult <https://www.elsevier.com/permissions>.

### **Author rights**

As an author you (or your employer or institution) have certain rights to reuse your work. [More information](#).

### **Ethics in publishing**

Please see our information pages on [Ethics in publishing](#) and [Ethical guidelines for journal publication](#).

### **Studies in humans and animals**

If the work involves the use of human subjects, the author should ensure that the work described has been carried out in accordance with [The Code of Ethics of the World Medical Association](#) (Declaration of Helsinki) for experiments involving humans. The manuscript should be in line with the [Recommendations for the Conduct, Reporting, Editing and Publication of Scholarly Work in Medical Journals](#) and aim for the inclusion of representative human populations (sex, age and ethnicity) as per those recommendations. The terms [sex and gender](#) should be used correctly.

Authors should include a statement in the manuscript that informed consent was obtained for experimentation with human subjects. The privacy rights of human subjects must always be observed.

All animal experiments should comply with the [ARRIVE guidelines](#) and should be carried out in accordance with the U.K. Animals (Scientific Procedures) Act, 1986 and associated guidelines, [EU Directive 2010/63/EU for animal experiments](#), or the National Institutes of Health guide for the care and use of Laboratory animals (NIH Publications No. 8023, revised 1978) and the authors should clearly indicate in the manuscript that such guidelines have been followed. The sex of animals must be indicated, and where appropriate, the influence (or association) of sex on the results of the study.

### **Declaration of competing interest**

All authors must disclose any financial and personal relationships with other people or organizations that could inappropriately influence (bias) their work. Examples of potential conflicts of interest include employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications/registrations, and grants or other funding. Authors should complete the declaration of competing interest statement using [this template](#) and upload to the submission system at the Attach/Upload Files step. **Note: Please do not convert the .docx template to another file type. Author signatures are not required.** If there are no interests to declare, please choose the first option in the template. This statement will be published within the article if accepted. [More information](#).

### **Declaration of Interest**

All authors must disclose any financial and personal relationships with other people or organizations that could inappropriately influence (bias) their work. Examples of potential conflicts of interest include employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications/registrations, and grants or other funding. If there are no conflicts of interest then please state this: 'Conflicts of interest: none'. [More information](#). The corresponding author must submit a completed [Authorship Contribution Form](#) and an [ICMJE Disclosure Form](#) with their submission on behalf of the author team. These forms enable the corresponding author to record the contribution of each author and disclose any potential or actual conflicts of interest that could influence, or be perceived to influence, the work. The forms must be signed in ink by the corresponding author, scanned, and uploaded to EVISE with the manuscript.

### **Contributors**

Each author is required to declare his or her individual contribution to the article: all authors must have materially participated in the research and/or article preparation, so roles for all authors should be listed using the following headings, Conception and Design, Data Collection, Analysis and Interpretation of Data, Manuscript Writing, Approval of Final Article. The statement that all authors have approved the final article should be true and included in the disclosure.

### **Submission declaration**

Submission of an article implies that the work described has not been published previously (except in the form of an abstract, a published lecture or academic thesis, see '[Multiple, redundant or concurrent publication](#)' for more information), that it is not under consideration for publication elsewhere, that its publication is approved by all authors and tacitly or explicitly by the responsible authorities where the work was carried out, and that, if accepted, it will not be published elsewhere in the same form, in English or in any other language, including electronically without the written consent of the copyright-holder.

### **Preprints**

Please note that [preprints](#) can be shared anywhere at any time, in line with Elsevier's [sharing policy](#). Sharing your preprints e.g. on a preprint server will not count as prior publication (see '[Multiple, redundant or concurrent publication](#)' for more information).

### **Use of inclusive language**

Inclusive language acknowledges diversity, conveys respect to all people, is sensitive to differences, and promotes equal opportunities. Content should make no assumptions about the beliefs or commitments of any reader; contain nothing which might imply that one individual is superior to another on the grounds of age, gender, race, ethnicity, culture, sexual orientation, disability or health condition; and use inclusive language throughout. Authors should ensure that writing is free from bias, stereotypes, slang, reference to dominant culture and/or cultural assumptions. We advise to seek gender neutrality by using plural nouns ("clinicians, patients/clients") as default/wherever possible to avoid using "he, she," or "he/she." We recommend avoiding the use of descriptors that refer to personal attributes such as age, gender, race, ethnicity, culture, sexual orientation, disability or health condition unless they are relevant and valid. These guidelines are meant as a point of reference to help identify appropriate language but are by no means exhaustive or definitive.

### *Article transfer service*

This journal is part of our Article Transfer Service. This means that if the Editor feels your article is more suitable in one of our other participating journals, then you may be asked to consider transferring the article to one of those. If you agree, your article will be transferred automatically on your behalf with no need to reformat. Please note that your article will be reviewed again by the new journal.

[More information.](#)

### **Role of the funding source**

You are requested to identify who provided financial support for the conduct of the research and/or preparation of the article and to briefly describe the role of the sponsor(s), if any, in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the article for publication. If the funding source(s) had no such involvement then this should be stated.

### **Open access**

Please visit our [Open Access page](#) for more information.

### *Elsevier Researcher Academy*

[Researcher Academy](#) is a free e-learning platform designed to support early and mid-career researchers throughout their research journey. The "Learn" environment at Researcher Academy offers several interactive modules, webinars, downloadable guides and resources to guide you through the process of writing for research and going through peer review. Feel free to use these free resources to improve your submission and navigate the publication process with ease.

### *Language (usage and editing services)*

Please write your text in good English (American or British usage is accepted, but not a mixture of these). Authors who feel their English language manuscript may require editing to eliminate possible grammatical or spelling errors and to conform to correct scientific English may wish to use the [English Language Editing service](#) available from Elsevier's Author Services.

### *Submission by an editor*

A paper submitted by an editor or board member (including submission as a co-author) will be handled by one of the other Senior Editors who will manage the peer review process. The Journal's submission system does not allow Editors to manage their own papers in the system.

### **Informed consent and patient details**

Studies on patients or volunteers (including retrospective studies and those from population databases) require ethics committee approval and informed consent, which should be documented in the paper. Appropriate consents, permissions and releases must be obtained where an author wishes to include case details or other personal information or images of patients and any other individuals in an Elsevier publication. Written consents must be retained by the author and copies of the consents or evidence that such consents have been obtained must be provided to Elsevier on request. For more information, please review the Elsevier Policy on the Use of Images or Personal Information of Patients or other Individuals. Unless you have written permission from the patient (or, where applicable, the next of kin), the personal details of any patient included in any part of the article and in any supplementary materials (including all illustrations and videos) must be removed before submission.

### *Reporting clinical trials*

Randomized controlled trials should be presented according to the CONSORT guidelines. At manuscript submission, authors must provide the CONSORT checklist accompanied by a flow diagram that illustrates the progress of patients through the trial, including recruitment, enrollment, randomization, withdrawal and completion, and a detailed description of the randomization procedure. The CONSORT checklist and template flow diagram are available online.

### *Acknowledgements*

List here those individuals who provided help during the research (e.g., providing language help, writing assistance or proofreading the article, etc.).

### **General points**

We accept most word processing formats, but Word, WordPerfect or LaTeX is preferred. Always keep a backup copy of the electronic file for reference and safety. Save your files using the default extension of the program used.

Please write your text in good English (American or British usage is accepted, but not a mixture of these). Italics are not to be used for expressions of Latin origin, for example, *in vivo*, *et al.*, *per se*. Use decimal points (not commas); use a comma for thousands (1,000 and above).

### *Language Services:*

Authors who require information about language editing and copyediting services pre- and post-submission please visit <https://www.elsevier.com/languagepolishing> for more information. Please note Elsevier neither endorses nor takes responsibility for any products, goods or services offered by outside vendors through our services or in any advertising. For more information please refer to our Terms and Conditions <https://www.elsevier.com/termsandconditions>.

### *Presentation of the Manuscript:*

Provide the following data on the title page (in the order given).

*Title.* Concise and informative. Titles are often used in information-retrieval systems. Avoid abbreviations and formulae where possible.

*Author names and affiliations.* Where the family name may be ambiguous (e.g., a double name), please indicate this clearly. Present the authors' affiliation addresses (where the actual work was done) below the names. Indicate all affiliations with a lower-case superscript letter immediately after the author's name and in front of the appropriate address. Provide the full postal address of each affiliation, including the country name, and, if available, the e-mail address of each author.

*Corresponding author.* Clearly indicate who is willing to handle correspondence at all stages of refereeing and publication, also post-publication. **Ensure that telephone and fax numbers (with country and area code) are provided in addition to the e-mail address and the complete postal address.**

*Present/permanent address.* If an author has moved since the work described in the article was done, or was visiting at the time, a "Present address" (or "Permanent address") may be indicated as a footnote to that author's name. The address at which the author actually did the work must be retained as the main, affiliation address. Superscript Arabic numerals are used for such footnotes.

*Abstract.* A concise and factual abstract of no more than 250 words is required. The abstract must be structured for original research articles, articles reporting the results of clinical trials, and short communications. The abstract should be divided by subheadings as follows: Objectives, Materials and Methods, Results and Conclusion.

The abstract should **not** be structured for review articles. The abstract should state briefly the purpose of the research, the principal results and major conclusions. An abstract is often presented separate from the article, so it must be able to stand alone.

**Keywords.** Immediately after the abstract, provide a maximum of ten keywords, avoiding general and plural terms and multiple concepts (avoid, for example, "and", "of"). Be sparing with abbreviations: only abbreviations firmly established in the field may be eligible. These keywords will be used for indexing purposes.

**Abbreviations.** Define all abbreviations at their first occurrence in the article: in the abstract but also in the main text after it. Ensure consistency of abbreviations throughout the article.

**Subdivision of the article.** Divide your article into clearly defined sections. Each subsection is given a brief heading. Each heading should appear on its own separate line. Subsections should be used as much as possible when cross-referencing text: refer to the subsection by heading as opposed to simply "the text."

**Introduction.** State the objectives of the work and provide an adequate background, avoiding a detailed literature survey or a summary of the results.

**Experimental/Materials and methods.** Provide sufficient detail to allow the work to be reproduced. Methods already published should be indicated by a reference: only relevant modifications should be described.

**Results.** Results should be clear and concise.

**Discussion.** This should explore the significance of the results of the work, not repeat them.

**Appendices.** If there is more than one appendix, they should be identified as A, B, etc. Formulae and equations in appendices should be given separate numbering: (Eq. A.1), (Eq. A.2), etc.; in a subsequent appendix, (Eq. B.1) and so forth.

**Conflict of interest.** Please include all conflicts of interest and disclosures by author.

**Author contributions.** Please include all contributions by author. **Acknowledgements.** Place acknowledgements before the references, in a separate section, and not as a footnote on the title page.

**Figure captions, tables, figures, schemes**

. Present these at the end of the article. They are described in more detail below. High-resolution graphics files should be provided separate from the main text file (see *Preparation of illustrations*). Ideally tables should be embedded in the main document after references rather than uploaded as individual documents. Figures can either be embedded in the main file or attached separately.

**Tables.** Number tables consecutively in accordance with their appearance in the text. Place footnotes to tables below the table body and indicate them with superscript lowercase letters. Avoid vertical rules. Be sparing in the use of tables and ensure that the data presented in tables do not duplicate results described elsewhere in the article.

**Nomenclature and units.** Follow internationally accepted rules and conventions: use the international system of units (SI). If other quantities are mentioned, give their equivalent in SI.

**Technical Information.** Identify precisely all drugs and chemicals used, including generic name(s), dose(s), and route(s) of administration. Identify appropriate scientific names and gene names.

**Preparation of supplementary data.** Elsevier accepts supplementary material to support and enhance your scientific research. Supplementary files offer the author additional possibilities to publish supporting applications, movies, animation sequences, high-resolution images, background datasets, sound clips and more. Supplementary files supplied will be published online alongside the electronic version of your article in Elsevier Web products, including ScienceDirect: <http://www.sciencedirect.com>. In order to ensure that your submitted material is directly usable, please ensure that data is provided in one of our recommended file formats. Authors should submit

the material in electronic format together with the article and supply a concise and descriptive caption for each file. For more detailed instructions please visit our artwork instruction pages at <https://www.elsevier.com/artworkinstructions>.

#### *Citation in text*

Please ensure that every reference cited in the text is also present in the reference list (and vice versa). Any references cited in the abstract must be given in full. Unpublished results and personal communications are not recommended in the reference list, but may be mentioned in the text. If these references are included in the reference list they should follow the standard reference style of the journal and should include a substitution of the publication date with either 'Unpublished results' or 'Personal communication'. Citation of a reference as 'in press' implies that the item has been accepted for publication.

#### *Reference links*

Increased discoverability of research and high quality peer review are ensured by online links to the sources cited. In order to allow us to create links to abstracting and indexing services, such as Scopus, CrossRef and PubMed, please ensure that data provided in the references are correct. Please note that incorrect surnames, journal/book titles, publication year and pagination may prevent link creation. When copying references, please be careful as they may already contain errors. Use of the DOI is highly encouraged.

A DOI is guaranteed never to change, so you can use it as a permanent link to any electronic article. An example of a citation using DOI for an article not yet in an issue is: VanDecar J.C., Russo R.M., James D.E., Ambeh W.B., Franke M. (2003). Aseismic continuation of the Lesser Antilles slab beneath northeastern Venezuela. *Journal of Geophysical Research*, <https://doi.org/10.1029/2001JB000884>. Please note the format of such citations should be in the same style as all other references in the paper.

#### *Web references*

As a minimum, the full URL should be given and the date when the reference was last accessed. Any further information, if known (DOI, author names, dates, reference to a source publication, etc.), should also be given. Web references can be listed separately (e.g., after the reference list) under a different heading if desired, or can be included in the reference list.

#### *Reference style*

*Text:* Indicate references by superscript numbers in the text. The actual authors can be referred to, but the reference number(s) must always be given.

*List:* Number the references in the list in the order in which they appear in the text.

#### *Examples:*

Reference to a journal publication:

1. Van der Geer J, Hanraads JAJ, Lupton RA. The art of writing a scientific article. *J Sci Commun* 2010;**163**:51–9. <https://doi.org/10.1016/j.Sc.2010.00372>.

Reference to a journal publication with an article number:

2. Van der Geer J, Hanraads JAJ, Lupton RA. The art of writing a scientific article. *Heliyon*. 2018;**19**:e00205. <https://doi.org/j.heliyon.2018.e00205>.

Reference to a book:

3. Strunk Jr W, White EB. *The elements of style*. 4th ed. New York: Longman; 2000.

Reference to a chapter in an edited book:

4. Mettam GR, Adams LB. How to prepare an electronic version of your article. In: Jones BS, Smith RZ, editors. *Introduction to the electronic age*, New York: E-Publishing Inc; 2009, p. 281–304.

Reference to a website:

5. Cancer Research UK. Cancer statistics reports for the UK, <http://www.cancerresearchuk.org/aboutcancer/statistics/cancerstatsreport/>; 2003 [accessed 13 March 2003].

Reference to a dataset:

[dataset] 6. Oguro M, Imahiro S, Saito S, Nakashizuka T. Mortality data for Japanese oak wilt disease and surrounding forest compositions, Mendeley Data, v1; 2015. <https://doi.org/10.17632/xwj98nb39r.1>.

Note shortened form for last page number. e.g., 51–9, and that for more than 6 authors the first 6 should be listed followed by 'et al.' For further details you are referred to 'Uniform Requirements for Manuscripts submitted to Biomedical Journals' (*J Am Med Assoc* 1997;**277**:927–34)(see also [Samples of Formatted References](#)).

Note shortened form for last page number. e.g., 51-9, and that for more than 6 authors the first 6 should be listed followed by "et al." For further details you are referred to "Uniform Requirements for Manuscripts submitted to Biomedical Journals" (J Am Med Assoc 1997;277:927-934) (see also [http://www.nlm.nih.gov/tsd/serials/terms\\_cond.html](http://www.nlm.nih.gov/tsd/serials/terms_cond.html)) The digital object identifier (DOI) may be used to cite and link to electronic documents. The DOI consists of a unique alpha-numeric character string which is assigned to a document by the publisher upon the initial electronic publication. The assigned DOI never changes. Therefore, it is an ideal medium for citing a document, particularly 'Articles in press' because they have not yet received their full bibliographic information. The correct format for citing a DOI is shown as follows (example taken from a document in the journal Physics Letters B): <https://doi.org/10.1016/j.physletb.2003.10.071> When you use the DOI to create URL hyperlinks to documents on the web, they are guaranteed never to change.

### **Data visualization**

Include interactive data visualizations in your publication and let your readers interact and engage more closely with your research. Follow the instructions [here](#) to find out about available data visualization options and how to include them with your article.

### **Formatting of electronic illustrations**

#### *General points*

Make sure to use uniform lettering and sizing for all original artwork. Save text in illustrations as "graphics" or enclose the font. Only use the following fonts in all illustrations: Arial, Courier, Helvetica, Times, Symbol. Number the illustrations according to their sequence in the text. Use a logical naming convention for all artwork files. Provide all illustrations as separate files and as hardcopy printouts on separate sheets. Provide captions to illustrations separately. Produce images near to the desired size of the printed version. A detailed guide on electronic artwork is available on our website: <https://www.elsevier.com/artworkinstructions>

#### *Formats*

Regardless of the application used, when electronic artwork is finalised, please "save as" or convert the images to one of the following formats (Note the resolution requirements for line drawings, halftones, and line/halftone combinations given below.):

EPS: Vector drawings. Embed the font or save the text as "graphics".

TIFF: Colour or greyscale photographs (halftones): always use a minimum of 300 dpi. TIFF: Bitmapped line drawings: use a minimum of 1000 dpi.

TIFF: Combinations bitmapped line/half-tone (colour or greyscale): a minimum of 500 dpi is required. DOC, XLS or PPT: If your electronic artwork is created in any of these Microsoft Office applications please supply "as is".

#### **Please do not:**

Supply embedded graphics in word processor (spreadsheet, presentation) document; Supply files that are optimised for screen use (like GIF, BMP, PICT, WPG); the resolution is too low; Supply files that are too low in resolution; Submit graphics that are disproportionately large for the content.

#### *Captions*

Ensure that each illustration has a caption. Supply captions separately, not attached to the figure. A caption should comprise a brief title (not on the figure itself) and a description of the illustration. Keep text in the illustrations themselves to a minimum but explain all symbols and abbreviations used.

#### *Line drawings*

The lettering and symbols, as well as other details, should have proportionate dimensions, so as not to become illegible or unclear after possible reduction; in general, the figures should be designed for a reduction factor of two to three. The degree of reduction will be determined by the Publisher. Illustrations will not be enlarged. Consider the page format of the journal when designing the illustrations. Do not use any type of shading on computer-generated illustrations.

#### *Colour illustrations*

Please make sure that artwork files are in an acceptable format (TIFF, EPS or MS Office files) and with the correct resolution. If, together with your accepted article, you submit usable colour figures then Elsevier will ensure, at no additional charge, that these figures will appear in colour on the Web (e.g., ScienceDirect and other sites) regardless of whether or not these illustrations are reproduced in colour in the printed version. For colour reproduction in print, you will receive information regarding

the costs from Elsevier after receipt of your accepted article. Please indicate your preference for colour in print or on the Web only. For further information on the preparation of electronic artwork, please see <https://www.elsevier.com/artworkinstructions>.

### *Revised Manuscripts*

Following the peer-review process, the Editor-in-Chief may ask for a revised manuscript to be prepared and re-submitted to the journal. The Journal of Geriatric Oncology requires that authors upload two separate files of the revised manuscript: o One file with the changes that have been made to the manuscript highlighted in some way, either by text highlighting or by using the 'track changes' tool found in many word processing software, and; o One file which contains a 'clean copy' of the revised manuscript. Please note that this refers to the revised manuscript, but without any highlighting of the changes that have been made. If the revised manuscript is accepted for publication, this file will be used for production purposes. Authors are asked not to re-upload their original manuscript.

### *Mendeley Data*

This journal supports Mendeley Data, enabling you to deposit any research data (including raw and processed data, video, code, software, algorithms, protocols, and methods) associated with your manuscript in a free-to-use, open access repository. During the submission process, after uploading your manuscript, you will have the opportunity to upload your relevant datasets directly to *Mendeley Data*. The datasets will be listed and directly accessible to readers next to your published article online.

For more information, visit the [Mendeley Data for journals page](#).

## **RESEARCH DATA**

This journal encourages and enables you to share data that supports your research publication where appropriate, and enables you to interlink the data with your published articles. Research data refers to the results of observations or experimentation that validate research findings. To facilitate reproducibility and data reuse, this journal also encourages you to share your software, code, models, algorithms, protocols, methods and other useful materials related to the project.

Below are a number of ways in which you can associate data with your article or make a statement about the availability of your data when submitting your manuscript. If you are sharing data in one of these ways, you are encouraged to cite the data in your manuscript and reference list. Please refer to the "References" section for more information about data citation. For more information on depositing, sharing and using research data and other relevant research materials, visit the [research data](#) page.

### **Data linking**

If you have made your research data available in a data repository, you can link your article directly to the dataset. Elsevier collaborates with a number of repositories to link articles on ScienceDirect with relevant repositories, giving readers access to underlying data that gives them a better understanding of the research described.

There are different ways to link your datasets to your article.

When available, you can directly link your dataset to your article by providing the relevant information in the submission system. For more information, visit the [database linking page](#).

For [supported data repositories](#) a repository banner will automatically appear next to your published article on ScienceDirect.

In addition, you can link to relevant data or entities through identifiers within the text of your manuscript, using the following format: Database: xxxx (e.g., TAIR: AT1G01020; CCDC: 734053; PDB: 1XFN).

### **Mendeley Data**

This journal supports Mendeley Data, enabling you to deposit any research data (including raw and processed data, video, code, software, algorithms, protocols, and methods) associated with your manuscript in a free-to-use, open access repository. Before submitting your article, you can deposit the relevant datasets to *Mendeley Data*. Please include the DOI of the deposited dataset(s) in your main manuscript file. The datasets will be listed and directly accessible to readers next to your published article online.

For more information, visit the [Mendeley Data for journals page](#).

### **Data statement**

To foster transparency, we encourage you to state the availability of your data in your submission. This may be a requirement of your funding body or institution.

If your data is unavailable to access or unsuitable to post, you will have the opportunity to indicate why during the submission process, for example by stating that the research data is confidential. The statement will appear with your published article on ScienceDirect. For more information, visit the [Data statement](#) page

### **Online proof correction**

To ensure a fast publication process of the article, we kindly ask authors to provide us with their proof corrections within two days. Corresponding authors will receive an e-mail with a link to our online proofing system, allowing annotation and correction of proofs online. The environment is similar to MS Word: in addition to editing text, you can also comment on figures/tables and answer questions from the Copy Editor. Web-based proofing provides a faster and less error-prone process by allowing you to directly type your corrections, eliminating the potential introduction of errors.

If preferred, you can still choose to annotate and upload your edits on the PDF version. All instructions for proofing will be given in the e-mail we send to authors, including alternative methods to the online version and PDF.

We will do everything possible to get your article published quickly and accurately. Please use this proof only for checking the typesetting, editing, completeness and correctness of the text, tables and figures. Significant changes to the article as accepted for publication will only be considered at this stage with permission from the Editor. It is important to ensure that all corrections are sent back to us in one communication. Please check carefully before replying, as inclusion of any subsequent corrections cannot be guaranteed. Proofreading is solely your responsibility.

### **Electronic offprints**

The corresponding author will, at no cost, receive a customized Share Link providing 50 days free access to the final published version of the article on ScienceDirect. The Share Link can be used for sharing the article via any communication channel, including email and social media. For an extra charge, paper offprints can be ordered via the offprint order form which is sent once the article is accepted for publication. Both corresponding and co-authors may order offprints at any time via Elsevier's Webshop. Corresponding authors who have published their article open access do not receive a Share Link as their final published version of the article is available open access on ScienceDirect and can be shared through the article DOI link.

© Copyright 2018 Elsevier | <https://www.elsevier.com>